Issue Archive
|
About Us
|
Contact Us
|
Subscribe
|
Editorial Board
|
Author Guidelines
|
About Haymarket Media
Home
News
Web Exclusives
Daily Oncology News
In the News
New Drug Products
ASH 2011
ASCO 2011
ONS Annual Congress 2011
ASH 2010
CE
CE Articles
mycme.com
Departments
Advisor Forum
Ask a Pharmacist
Case Study
Communication Challenges
From CancerCare
In the News
Issues in Cancer Survivorship
Radiation and Your Patient
Reflections
Stat Consult
The Patient's Voice
The Total Patient
Issue Archive
Topics
Chemotherapy
Communication
End-of-Life Issues
Pain Management
Palliative Care
Radiology
Side-Effect Management
Survivorship
Women's Health
Cancer Types
Brain Cancer
Breast Cancer
Cervical Cancer
Colorectal Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Head and Neck Cancer
Kidney Cancer
Leukemia
Liver Cancer
Lung Cancer
Lymphoma
Melanoma
Multiple Myeloma
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Sarcoma
Skin Cancer
Chemotherapy Regimens
Clinical Trials
Brain Cancer
Breast Cancer
Cervical Cancer
Colorectal Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Head and Neck Cancer
Kidney Cancer
Leukemia
Liver Cancer
Lung Cancer
Lymphoma
Melanoma
Multiple Myeloma
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Sarcoma
Skin Cancer
For Your Patient
Advocacy
CancerCare Fact Sheets
Cancer Support Groups
Financial Assistance
Finding Clinical Trials
Palliative Care and Hospice
Patient Information
The Total Nurse
General Medicine in Oncology
Slideshows
Supplements
Jobs
Tools & Links
RSS
|
Login
|
Register
ONA
> Issue Archive
ONA 2012 Issue Archive
Choose another year:
2012
|
2011
|
2010
February 2012
Web Exclusives
Side effects of certain cancer drugs may be fatal
Delicia Honen Yard
February 22, 2012
Sorafenib, sunitinib, and pazopanib have been found to carry a heightened risk of fatal complications, but the incidence remains low overall.
High-definition blood test may become comparable to biopsy
Delicia Honen Yard
February 21, 2012
An advanced blood test that detects and analyzes circulating tumor cells provides data that could soon compare to that obtained from biopsies.
Two approaches recommended to reduce oxaliplatin toxicity during colorectal therapy
Delicia Honen Yard
February 20, 2012
A review addresses the need to balance the effectiveness of oxaliplatin against its dose-limiting complication of neurotoxicity.
more »